

1 March 2017

ASX Announcement
Preliminary Financial results for the year ending 31 December 2016

Highlights for the year ending 31 December 2016 include:

- Cash at bank at 31 December 2016 of \$7.611M.
- Total Current Assets at 31 December 2016 of \$8.225M.
- Successful completion of the acquisition of BodyTel GmbH and Lifespot AG on 28 December 2016, with revenues to be reported in future reporting periods.
- Completion of successful IPO raising maximum amount of \$8M.
- A record month for BodyTel in December 2016 (pre-acquisition), with month-on-month revenue growth of over 20%, well above budgeted forecasts. The strong underlying growth is expected to increase in 2017, further cementing the company's position in the global market for the management & monitoring of chronic diseases.

Lifespot Health Limited (Company) announces its preliminary financial results for the year ending 31 December 2016.

It is important to note that the completion of the acquisition of BodyTel GmbH and Lifespot AG occurred on 28 December 2016. Accordingly, pre-acquisition revenues from BodyTel GmbH and Lifespot AG are not recorded in the Company's financial statements for the year ending 31 December 2016. Reported revenues of \$1,000 (mainly interest received), were generated between 29 December 2016 and 31 December 2016.

Prior to gaining control, reported annual revenues for BodyTel GmbH in 2016 were 594,520€ (\$819,519 AUD), increasing from 178,521€ (\$246,084 AUD) in H1 2016 to 415,999€ (\$573,435 AUD) in H2 2016 representing strong underlying growth in the business, driven by new customer wins and projects.

Revenues from the Company's operating subsidiaries will be included for the full reporting period in all post 31 December 2016 financial reports.

Operational highlights during the period include the completion of the acquisition BodyTel GmbH and Lifespot AG and completion of a successful IPO.

The capital raising received strong support and was oversubscribed with the maximum amount of \$8M being raised. Lifespot Health was pleased to attract investment in the capital raising from top-tier global institutions and small cap funds, which invest strategically into Healthcare IT.

As announced on 16 January 2017, BodyTel achieved record sales in December 2016 (pre-acquisition), with month-on-month revenue growth of over 20%, well above budgeted forecasts. The strong underlying growth is expected to increase in 2017, further cementing the company's position in the global market for the management & monitoring of chronic diseases.

ENDS

For further information:

Mr Niv Dagan
Corporate Advisor
Peak Asset Management

Mr Justyn Stedwell
Company Secretary
Lifespot Health Ltd

Phone: 1300 304 460
Mobile: 0402 912 198

Phone: 03 9 041 6663

About Lifespot Health Ltd.

Lifespot Health operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology. Our systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money.

Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients to monitor chronic diseases and critical conditions with their smartphones.

For personal use only

Lifespot Health Ltd ACN 611 845 820 and Controlled Entities

Financial report for the period ended 31 December 2016

APPENDIX 4E – PRELIMINARY FINAL REPORT FOR THE PERIOD ENDED 31 DECEMBER 2016

Results for Announcement to the Market

Reporting Period: 13 April 2016 (Date of Incorporation) to 31 December 2016

Previous Period: Not applicable

1. Key Information	2016 \$000	2015 \$000	% Change
Revenue from ordinary activities	1	n/a	n/a
Profit/(Loss) after tax from ordinary activities attributable to members	(348)	n/a	n/a
Net Profit/(Loss) attributable to members	(348)	n/a	n/a

2. Dividends Paid and Proposed

	Amount per Security	Franked Amount per Security at 30% of Tax
Ordinary shares:		
2016 interim – paid	-	-
2016 final – declared	-	-
Record date for determining entitlements to the dividends:		
Ordinary shares	n/a	n/a

Explanation of Key Information and Dividends

The company was established on 13 April 2016 and the controlled entities acquired 28 December 2016, hence limited revenue and expenses are recorded in the current financial year - refer further, Section 14

APPENDIX 4E – PRELIMINARY FINAL REPORT

3. CONDENSED CONSOLIDATED OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 DECEMBER 2016

	Consolidated Group
	2016
	\$000
Continuing operations	
Trading Revenue	-
Other income	1
Directors' Fees	(190)
Travel	(43)
Entertainment	(35)
Other expenses	(81)
(Loss) before income tax	(348)
Tax expense	-
Net (Loss) from continuing operations	(348)
Profit/(Loss) from discontinued operations after tax	-
Net (Loss) for the year	(348)
Other comprehensive income for the period	-
Total comprehensive Income/(Loss) attributable as follows:	(348)
Members of the parent entity	(348)
Non-controlling interest	-
	(348)
Earnings per share	
From continuing and discontinued operations:	
Basic earnings per share (cents)	(1.35)
Diluted earnings per share (cents)	(1.31)
From continuing operations:	
Basic earnings per share (cents)	(1.35)
Diluted earnings per share (cents)	(1.31)
From discontinued operations:	
Basic earnings/(loss) per share (cents)	-
Diluted earnings per share (costs)	-

For personal use only

APPENDIX 4E – PRELIMINARY FINAL REPORT

4. CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2016

	Consolidated Group
	2016
	\$000
ASSETS	
CURRENT ASSETS	
Cash and cash equivalents	7,611
Trade and other receivables	614
TOTAL CURRENT ASSETS	8,225
NON-CURRENT ASSETS	
Property, plant and equipment	27
Intangible assets	323
TOTAL NON-CURRENT ASSETS	350
TOTAL ASSETS	8,575
LIABILITIES	
CURRENT LIABILITIES	
Trade and Other Payables	1,185
Deferred Tax	77
TOTAL CURRENT LIABILITIES	1,262
TOTAL LIABILITIES	1,262
NET ASSETS	7,313
EQUITY	
Issued capital	8,018
Options Reserve	220
Other Reserves	(577)
Accumulated Losses	(348)
Parent interest	7,313
Non-controlling interest	-
TOTAL EQUITY	7,313

For personal use only

APPENDIX 4E – PRELIMINARY FINAL REPORT

5. CONDENSED CONSOLIDATED STATEMENT OF CASHFLOWS FOR THE PERIOD
ENDED 31 DECEMBER 2016

	Consolidated Group 2016 \$000
Cashflows from operating activities:-	
Receipts from customers	1
Payments to suppliers and employees	(223)
Net cash (used in) operating activities	<u>(222)</u>
Cashflow from investing activities:-	
Payment for subsidiary, net of cash acquired (Note 1)	(439)
Payment for intangibles	(14)
Net cash (used in) investing activities	<u>(453)</u>
Cash flows from financing activities:-	
Cash proceeds from issue of shares (net of capital raising costs)	8,286
Net cash provided by/(used in) financing activities	<u>8,286</u>
Net increase in cash held	7,611
Cash and cash equivalents at beginning of financial period	-
Cash and cash equivalents at end of financial period	<u>7,611</u>

Note 1

Purchase consideration for controlled entities	\$000
Cash paid and payable	439
Fair value of shares issued (22,000,000 shares)	401
Working Capital Adjustment (receivable)	(299)
Total consideration	541
The assets and liabilities recognised as a result of the acquisition are as follows:-	
Cash	4
Trade Receivables and Prepayments	211
Property, plant & equipment	27
Intangible assets	309
Trade and Other Payables	(510)
Deferred Tax	(77)
Net identifiable assets acquired	(36)
Excess of net assets over purchase consideration paid recognised as reserves	577

APPENDIX 4E – PRELIMINARY FINAL REPORT

6. MOVEMENTS IN EQUITY FOR THE PERIOD ENDED 31 DECEMBER 2016

	Capital	Acc Losses	Options Reserve	Other Reserves	Total
	\$000	\$000	\$000	\$000	\$000
Issue of shares	9,249	-	-	-	9,249
Total comprehensive income	-	(348)	-	-	(348)
Capital raising costs	(1,231)	-	-	-	(1,231)
Options issued	-	-	220	-	220
Transaction between entities					
Under common control	-	-	-	(577)	(577)
Balance 31 December 2016	8,018	(348)	220	(577)	7,313

Notes:-

Total shares on issue (including Prospectus shares issued) – 31 December 2016 74,940,173

Options on issue (exercise price \$0.30) 7,550,000
(expiry 11 January 2020)

Options Reserve - 1,000,000 options issued to Directors & CEO
-1,000,000 options issued to Lead Manager and Promoters/Advisors

Other Reserves - transaction between entities under common control, hence variance between purchase price and net assets acquired recognised in equity.

APPENDIX 4E – PRELIMINARY FINAL REPORT

7. Dividend Details

	2016
	\$000
Ordinary share capital:	
Final dividend	-
Interim dividend	-

8. Dividend Reinvestment Plan

There was no dividend reinvestment plan in operation during the financial period

9. Net Tangible Assets per Share

	2016
	cents/share
Net tangible assets backing per ordinary share	9.36

10. Control Gained or Lost over Entities in the Year

On 28 December 2016, the Group acquired a 100% interest in Lifespot AG and BodyTel GMBH. These entities contributed \$12,612 loss to the Group's consolidated loss from ordinary activities during the period ended 31 December 2016.

11. Investment in Associates and Joint Ventures

	2016
	%
Material investments in associates and joint ventures are as follows:	-

12. Other Significant Information

None other than company was admitted to the official list of ASX Limited on 10 January 2017 – 74,940,173 fully paid ordinary shares quoted. Further, Dr P Bekhar became a director on 13 January 2017.

13. Accounting Standards

The Group financial statements are being prepared in accordance with Australian Accounting Standards and Interpretations of the Australian Accounting Standards Board and International Financial Reporting Standards issued by the IASB.

APPENDIX 4E – PRELIMINARY FINAL REPORT

14. Overview on the Results for the Period

Overview

The parent entity was incorporated on 13 April 2016. On 28 December 2016, it acquired a 100% interest in Lifspot AG and BodyTel GMBH. It aims to commercialise the Body System and the Lifspot Skin System, which are currently owned by the entities it acquired.

Significant Changes to Activities

There have been no significant changes in the nature of the principal activities during the financial period, other than the acquisitions referred to above, and the listing of the company in January 2017.

Segment Details

The Group's key operating segment is its body system and lifspot skin system segment which is one industry segment. Its key geographical segments are Australia (head office) and Germany (body system and lifspot skin system), details as follows at 31 December, 2016:

Revenue	\$000
Australia	1
Germany	-
Total	<u>1</u>

Assets	\$000
Australia	8,032
Germany	543
Total	<u>8,575</u>

Other

The parent entity successfully listed on the ASX following its prospectus being fully subscribed through the issue of 40 million shares at \$0.20 per share. There are no factors which have affected or are likely to affect future results of the Group, except as disclosed in this report.

Status of Audit

The financial report is currently being subject to audit.



Justyn Stedwell – Company Secretary – 28/2/17